Skip to content
DataLookout
Menu

DOMENICANCT05201547

Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

StatusActive, Not Recruiting
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 19 versions: 19 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 47 words Show 5 more changesShow less
    • Primary completion date changed from estimate of Apr 2026 to Oct 1, 2026
    • Secondary endpoints: 14 to 15
    • Site details revised at 10 of 100 sites
    • Publications: details revised at 2 of 2 entries
    • Study description expanded, about 3 words
  2. Minor Study sites revised (100)v18
  3. Minor Study sites: 95 to 100v17
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites revised (95)
    v16
  5. Minor Study sites: 84 to 95v15
Show 13 earlier versionsHide 13 earlier versions
  1. Notable Eligibility criteria shortened, about 3 words
    • Study sites: 81 to 84
    v14
  2. Minor Study sites: 59 to 81v13
  3. Minor Study sites: 49 to 59v12
  4. Minor Study sites: 47 to 49v11
  5. Minor Study title revisedv10
  6. Minor Study sites: 45 to 47v9
  7. Minor Study sites: 44 to 45v8
  8. Minor Secondary endpoints: details revised at 3 of 14 entriesv7
  9. Minor Secondary endpoints revised (14)v6
  10. Notable Enrollment target: 142 to 260v5 Show 4 more changesShow less
    • Eligibility criteria expanded, about 75 words
    • Study sites: 41 to 44
    • Secondary endpoints: 10 to 14
    • Study description expanded, about 10 words
  11. Notable Primary completion date: Jan 2025 to Apr 2026
    • Study sites: 37 to 41
    • Study completion date: May 2029 to Oct 2029
    v4
  12. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 2022 to Apr 15, 2022
    • Site details revised at 37 of 37 sites
    v3
  13. Minor Start date: Jan 2022 to Feb 2022v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression Free Survival (PFS)
Timeframe: from the date of randomization until objective tumor progression based on RECIST 1.1, or death due to any cause, whichever occurs first assessed up to 5 years.

Secondary (15)

Overall Survival (OS) (key secondary endpoint)
Progression Free Survival 2 (PFS2)
Quality Of Life evaluation based on Quality of Life Questionnaire EQ5D5L (The 5-level EQ-5D version)
To assess the effects of Dostarlimab on Health related quality of Life (QoL) based on EORTC QLQ C30 (Quality of Life questionnaire-core 30) (with a focus of role functionning dimension)
To assess the quantity of peripheral neuropathy event induced by chemotherapy based on EORTC QLQ-CIPN 20 (Quality of Life questionnaire-Chemotherapy induced peripheral neuropathy 20)
Show 10 moreShow less
To assess the effects of treatment on health-related quality of life (HRQoL) as measure by determining time to deterioration in Quality of life, based EORTC QLQ-EN24 (Quality of Life Questionnaire - Endometrial Cancer Module)
To assess the status of health for patients with endometrial cancer based on EUROQOL EQ-5D (Descriptive system)
Best Objective Response Rate (ORR)
Disease Control Rate (DCR)
Duration of Response Rate (DoR)
Safety and number of adverse events
Tolerability to the treatment
Time to first and second Subsequent Treatment
To determine the immunogenicity of dostarlimab
PRO-CTCAE Average composite score

Arms and interventions

Arm A: Dostarlimab 500 mg, every 3 weeks, 4 cycles and then 1000 mg every 6 weeksExperimental
Arm B: Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2, every 3 weeks, 6 cycles.Experimental

Drugs: Carboplatin-Paclitaxel, Dostarlimab

Sites

100 sites in 10 countries

France 54, Italy 14, Spain 9, South Korea 7, United Kingdom 6, Japan 4, Australia 2, Singapore 2, Canada 1, New Zealand 1